Objective: Cortical gray matter (GM) pathology, involving demyelination and neurodegeneration, associated with meningeal inflammation, could be important in determining disability progression in multiple sclerosis (MS). However, we need to know more about how cortical demyelination, neurodegeneration, and meningeal inflammation contribute to pathology at early stages of MS to better predict long-term outcome. Methods: Tissue blocks from short disease duration MS (n = 12, median disease duration = 2 years), progressive MS (n = 21, disease duration = 25 years), non-diseased controls (n = 11), and other neurological inflammatory disease controls (n = 6) were quantitatively analyzed by immunohistochemistry, immunofluorescence, and in situ hybridization. Results: Cortical GM demyelination was extensive in some cases of acute MS (range = 1-48% of total cortical GM), and subpial lesions were the most common type (62%). The numbers of activated (CD68 + ) microglia/macrophages were increased in cases with subpial lesions, and the density of neurons was significantly reduced in acute MS normal appearing and lesion GM, compared to controls (p < 0.005). Significant meningeal inflammation and lymphoid-like structures were seen in 4 of 12 acute MS cases. The extent of meningeal inflammation correlated with microglial/macrophage activation (p < 0.05), but not the area of cortical demyelination, reflecting the finding that lymphoid-like structures were seen adjacent to GM lesions as well as areas of partially demyelinated/remyelinated, cortical GM. Interpretation: Our findings demonstrate that cortical demyelination, neuronal loss, and meningeal inflammation are notable pathological hallmarks of acute MS and support the need to identify early biomarkers of this pathology to better predict outcome. ANN NEUROL 2018;84:829-842 M ultiple sclerosis (MS) is a highly variable and lifechanging condition, characterized by inflammation, demyelination, and neurodegeneration. MS typically presents as a relapsing-remitting disease, where bouts of acute inflammation and new, active, demyelinating lesions are associated with neurological impairment. Lesions of the gray matter (GM) occur at all stages of the disease, and the extent of cortical GM pathology predicts conversion to clinically definite MS and associates with cognitive and motor disability, epilepsy, and an earlier transition to the progressive phase.
secondary progressive MS. [3] [4] [5] [6] [7] [8] [9] [10] Inflammatory cells of the leptomeninges (T and B lymphocytes, plasma cells, and macrophages) are increased in number, can display a semiorganized lymphoid-like structure, and are typically seen in the deep cerebral sulci, but are also noted in the leptomeninges of the cerebellum and spinal cord. 3, 11, 12 Lymphoid-like structures (LLSs), which can resemble ectopic B-cell follicles seen in other autoimmune diseases, 13 are observed in models of MS and in approximately 40% of secondary progressive MS cases at postmortem. 5 Cases of progressive MS harboring elevated leptomeningeal immune cell infiltration and LLSs are associated with an early onset, shorter and more aggressive disease course, and more rapid accumulated disability than those in which LLSs could not be identified. 5 More recently, it has also been demonstrated that a signature of immune mediators important in lymphocyte homing and lymphoid neogenesis strongly predicts those people with early MS at risk of extensive neocortical atrophy and magnetic resonance imaging (MRI)-visible cortical lesions. 14 We analyzed a postmortem cohort of MS cases with short disease duration, who were diagnosed and died before the advent of disease-modifying therapies. We asked whether cortical lesions and neuronal loss are a feature of acute MS and whether leptomeningeal inflammation is a notable pathological feature at the earliest stages of the clinical disease. These findings help us better understand the pathogenetic mechanisms of cortical GM pathology in early disease and may have implications for the rational identification of prognostic molecular and/or radiological measures for this heterogeneous condition.
Subjects and Methods

Cohort Demographics
Human postmortem tissue samples (South West Wales Research Ethics Committee approval #13/WA/0292) provided by the Thomas Willis Oxford Brain Bank and the Queen's University Belfast Dame Ingrid Allen Demyelinating Diseases Tissue Collection were used to investigate the pathological features present at the earliest stages of MS. Cases of chronic progressive MS (primary and secondary progressive with disease duration >10 years) were provided by the UK MS Society Tissue Bank, Imperial College London (ethical approval #08/MRE09/31+5). Details of each case are listed in supplementary Table 1 .
Six-micrometer-thick, formalin-fixed, paraffin-embedded sections were cut from cerebral cortex and subcortical white matter (WM) blocks obtained from the superior frontal cortex, cingulate gyrus, occipital lobe, and anterior hippocampus/parahippocampal gyrus. Twelve cases of acute MS (9 female) were selected based on tissue availability and their short disease duration (median duration = 2 years, range = 0.3-4 years; median age at death = 35 years, range = 22-58 years; see supplementary Table 1 ). The cases of progressive MS represented a cohort of clinical and neuropathologically validated MS with evidence of active disease pathology, and comprised a minimum of three tissue blocks of frontal, cingulate, and temporal cortex per case (primary progressive MS, n = 3; secondary progressive MS, n = 18; 12 female; median age at death = 50 years, range = 38-66 years; disease duration = 25 years, range = 10-39 years). Anatomically matched tissue blocks from 11 non-neurological disease controls were used for comparison. Control case selection was based on tissue availability, cause of death, and the youngest possible age at death (median age = 56 years; range = 41-67 years). In addition, we obtained tissue from 6 neuroinflammatory disease controls (acute disseminated encephalomyelitis, n = 1; cytomegalovirus encephalitis, n = 3; neuromyelitis optica, n = 1; and comorbid meningoencephalitis with MS, n = 1) for qualitative analysis (see supplementary Table 1 ).
Tissue Characterization and Analysis
Tissue sections were stained with Luxol fast blue (LFB) and immunohistochemically stained with anti-proteolipid protein (PLP) and anti-CD68 antibodies to characterize demyelination and lesion inflammatory status, and parenchymal and meningeal connective tissue microglial/macrophage density. Sections were assessed for the degree of GM and WM demyelination, presence or absence of GM lesion types, and presence of areas of tissue that appeared to be partially de-/remyelinated cortical GM. Cortical GM lesions were categorized following published criteria with evidence of active demyelination; and (4) inactive lesions, with little increase in the number of CD68 + microglia/macrophages at the lesion edge and no evidence of recent myelin phagocytosis. Fully remyelinated WM lesions were classified as shadow plaques based on the "normally appearing" PLP profile and classic LFB "shadow" appearance, 18 whereas partial or incompletely remyelinated areas were referred to as remyelinating lesions. We acknowledge that the above characterization only refers to the sampled area of incomplete lesions as present in standard histology sections. 17 The relative inflammatory status of cases was graded by assessing the degree of total cellular infiltration (Nissl counterstained cellular infiltrates) of GM and WM vessels and the meninges. 5 Briefly, absence or mild inflammation was rated 0+ (zero to 5 cells), diffuse and modest inflammation was rated ++ (equivalent to an infiltrate of 5-50 loosely packed cells in perivascular space or meninges), and more substantial infiltration was rated +++ (based on >50 cells in a tightly packed infiltrate, characteristic of a putative lymphoid-like structure).
Immunohistochemistry
Individual antibody details are listed in Table 1 . Briefly, following dewaxing, rehydration, epitope retrieval and blocking, slides were incubated with primary antibody overnight. Species-specific biotinylated secondary antibody (raised in horse or goat; Vector Laboratories, Peterborough, UK) was applied and antibody binding was visualized with the avidin-biotin-complex (ABC) peroxidase-linked reporter system, with 3, 3 0 -diaminobenzidine (DAB; Impact DAB, Vector Laboratories) as the chromogen. Tissue sections were counterstained with hematoxylin and DePex mounted. Dual color immunohistochemistry was performed sequentially. Primary antibody 1 was detected using the IMPRESS-peroxidase detection kit (Vector Laboratories), using DAB as the reporter chromogen. Primary antibody 2 was detected using the ABC-alkaline phosphatase detection system, using Vector Blue as the substrate. When using 2 primary antibodies raised in the same species (for dual CD20 and antiproliferating cell nuclear antigen [PCNA]), the slides were subjected to an additional round of heat retrieval in between the detection of primary antibody 1 and primary antibody 2, as described previously.
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For immunofluorescence, relevant primary antibodies were amplified using the IMPRESS Dylight reaction kit (Vector Laboratories) or via biotin-streptavidin-fluorophore (Alexa 488 or Alexa 546) conjugates (Merck Millipore, Watford, UK). All sections were counterstained with 4 0 ,6-diamidino- 
Quantitative Morphometry
Histological or immunohistochemically stained tissue sections for LFB, PLP, CD68, CD3, and HuC/D were digitized by whole Anti-PCNA Proliferating cell nuclear antigen Dako Cytomation mAb/PC10 1:1,000
Antibody name, target cell, commercial source, and working dilution are listed. mAb, monoclonal mouse antibody; pc, polyclonal antibody.
slide scanning using an SCF400F scanner (Leica, Wetzlar, Germany). Image files were handled using QuPath. 22 To measure areas of demyelination, we first traced and measured the entire GM and WM fraction for each LFB/hematoxylin-stained slide using QuPath, before measuring the area of individual GM and WM lesions on the serial PLP/hematoxylin-stained section. 
Measuring Myelin Coverage and Defining Partially De-/Remyelinated Cortical GM
We used Fiji ImageJ (https://fiji.sc/) to determine the myelin coverage across the GM cortex in virtual ×40 magnification PLP snapshots exported from QuPath (image size = 2.25 × 3.75 mm). TIFF image snapshots were converted to grayscale before thresholding to mark all areas positive for anti-PLP-specific immunostain. Myelin density profiles were generated for the entire depth of the cortical ribbon from areas of "most normal" myelin and partially de-/remyelinated GM, in the same block and at the same architectonic point (ie, sampled from base of sulcus or midway between sulcus and crown of gyrus) using the plot-profile selection tool. Myelin density profiles (captured in triplicate) were averaged and reported for every 2% step along the depth of the sampled cortex. Density profiles at each step were then compared relative to the same point in the myelin density profile of matched "most normal" GM as described in Results.
Statistical Analysis
Results were presented as scatter dot plots with a line at the mean or as box and whisker plots showing minimum-tomaximum values, interquartile range, and group medians. Twogroup comparisons were made using the Mann-Whitney U test or Wilcoxon matched pairs test, whereas ≥3 groups were compared by nonparametric 1-way analysis of variance (KruskalWallis test) using Dunn multiple comparisons post-test. Associations between pathological variables were tested by Spearman analysis (Prism v6; GraphPad, La Jolla, CA).
Results
Cortical GM and WM Demyelination in Acute MS Anti-PLP immunostaining revealed extensive areas of WM demyelination and all 4 cortical GM lesion types in acute MS (Fig 1A-D) . Demyelinated cortical GM (as a percentage of total cortical GM) ranged from 1 to 48% (mean = 11.9%; see Fig 1E) , whereas WM demyelination ranged from 2 to 81%. Average WM lesion area was significantly greater than GM lesion area (34.3% vs 11.9%, p = 0.0007) at this stage. Progressive MS cortex had 3 times the extent of cortical GM demyelination as seen in acute MS (29.1% vs 11.9%, in progressive and acute MS, respectively, p = 0.03), with the area of GM demyelination being comparable to that of WM lesions in the same progressive MS cases (29.1% and 30.1% for GM and WM lesions, respectively). Subpial (type 3) cortical GM lesions were the most abundant cortical GM lesion type in acute MS (seen twice as frequently as all other GM lesion types combined; see Fig 1F) . A number of small type 2 intracortical lesions were noted in acute MS (accounting for 19% of all cortical GM lesions). Interestingly, the proportion of type 3 GM lesions was remarkably similar in progressive MS but we failed to observe a single type 2 lesion in late disease. We noted an increase in the number of type 1 and type 4 GM lesions (see Fig 1F) in progressive cases.
More than 50% (36 of 69) of the GM lesions displayed signs of active demyelination (active or chronic active GM lesions), with 12 of 69 GM lesions being categorized as fully active cortical GM lesions (being confluent in CD68 + microglia/macrophages containing PLP + inclusions; see Fig 1) . Only chronic active and chronic inactive cortical GM lesions were seen in progressive MS. Those cases displaying type 3 cortical GM lesions had significantly elevated numbers of anti-CD68 + microglia/ macrophages across the full depth of the cortex, in comparison to those acute MS cases without type 3 lesions (p = 0.001) or in comparison to non-neurological controls (p = 0.0002).
Neurodegeneration in Acute MS
A significant reduction in total HuC/D + neuron density was observed in MS NAGM (19.7% reduction, p = 0.0117) and MS GM containing type 3 lesions (34.3% reduction, p < 0.0001) in comparison to anatomically matched controls (Fig 2A, B) . We have previously shown that complement is activated in progressive MS GM neurons and complement activation correlated with severity of GM pathology, 21, 23 whereas others have shown that complement C1q and C3b expression is associated with degenerating synapses in the progressive MS hippocampus. 20 We performed ISH for complement transcripts that encode the recognition fragment C1q and the central complement component C3. We saw evidence of, but did not quantify, complement transcript-positive cells with a distinct neuronal morphology associated with IBA-1 + microglia, C1QA and C3 transcriptpositive cells with a neuronal morphology, and C1QA-positive cells dual labeled with anti-HuC/D (see Fig 2) .
WM Lesions in Acute MS
The majority of acute MS WM lesions were classified as active inflammatory demyelinating lesions (Fig 3A-D) , as might be expected for such a short disease duration cohort. Active WM lesions accounted for 74% of all identified WM lesions (39 lesions in total) in acute MS. The density of CD68 + microglia/macrophages was significantly elevated in active WM lesions in comparison to chronic active lesions, remyelinating and/or shadow plaques, normal appearing WM, and control WM (see Fig 3E, F) . cell division PCNA, and leukocytes expressing transcripts of the key lymphogenic cytokine CXCL13.
Identification of Leptomeningeal LLSs in Acute MS
Relationship between Meningeal Infiltrates, Parenchymal Microglial Activation, and Myelin Pathology in Acute MS LLSs in secondary progressive MS are typically associated with underlying areas of subpial cortical microglial activation and demyelination. Here, we report a significant and robust association between the number of leptomeningeal macrophages and CD3
+ lymphocytes (and a trend for CD20 + B lymphocytes, r = 0.69, p = 0.07) and the number of activated microglia/macrophages in the subpial GM parenchyma in those acute MS cases with LLSs (Table 2) . It was interesting to note that alongside LLSs, which were topographically associated with subpial GM lesions, we sometimes saw LLSs next to areas of incompletely de-/ remyelinated cortex (Fig 5) . Areas of partially de-/remyelinated cortical GM were identified based on a direct comparison to the most NAGM in the same section to moderate the effect of the natural variation in myelination between cortical areas. We observed that the density of PLP + immunostaining was reduced by up to 70% in the partially de-/remyelinated cortical GM in comparison to paired samples of adjacent NAGM. The area of significantly reduced PLP + signal extended from the pia to almost halfway across the depth of the cortex (on average 48% of the distance from the pia to the GM/WM border). Within this same tissue, the number of parenchymal CD68 + microglia/macrophages was significantly elevated in the partially de-/remyelinated cortical GM in comparison to matched samples of NAGM, whereas the number of meningeal CD68 + macrophages was increased in areas overlaying the affected cortical GM in comparison to the same areas of adjacent NAGM. The number of CD3 + and CD20 + lymphocytes was unchanged in the meninges overlying the partially de-/remyelinated GM in comparison to normal GM (data not shown). Supporting the impression that the partially de-/remyelinated GM may represent, at least in part, a pathological change, we noted CD68 + microglia containing PLP + inclusions of myelin and evidence of neurofilament-H + neuritic transections and end-bulb-like structures in the affected GM.
Discussion
We report that subpial cortical demyelination, neurodegeneration, and widespread microglial/macrophage activation, together with elevated meningeal inflammation and the presence of LLSs, are notable pathological features in the earliest years since diagnosis in some acute MS cases. These data have implications for our understanding of the pathology underlying MS and support efforts to develop biomarkers of meningeal inflammation and cortical demyelination early in the disease, to aid the identification of those at risk of a more severe MS course.
GM Demyelination Is Widespread and Active in Acute MS
The majority of neuropathological studies of cortical pathology have been conducted on cases of longstanding, progressive disease, 2 and it has been suggested that the buildup of cortical damage may be more prominent at the later stages. 9,10 Here, we analyzed an archival cohort in what is, at present, the largest study of cortical pathology in acute MS. The cohort is defined by a short disease duration, which we have termed acute MS, and all patients died before the advent of effective anti-inflammatory therapies. Cases of such short disease duration are rare, given the success of current immunomodulatory therapies. Therefore, this tissue cohort provides an important resource for the description of cortical pathology, including demyelination, neurodegeneration, and inflammation, in the early clinically apparent phase of the disease. Cortical GM lesions, especially subpial (or type 3) GM lesions, were frequently noted in both our acute and progressive MS cohorts. Cortical pathology and significant subpial demyelination have also been documented in biopsy tissue taken as part of the diagnosis of MS with an atypical presentation. 24 In contrast to our study, Kutzelnigg et al 9 reported only modest cortical demyelination (0-4% of total cortical GM measured from coronal macrosections) in a cohort of acute MS. Differences may partly be explained by the shorter disease duration (up to 7 months compared to 4 years in this study), a younger age at death leading to a more aggressive cortical pathology in our cohort, or that our sampling of small blocks (1-6 blocks per case) overestimates what might be a highly variable pattern of cortical demyelination when viewed across the whole forebrain. However, these findings do suggest that the mechanisms that drive cortical lesion formation in acute MS may be the same as those that contribute to cortical pathology in long-term disease and are already present at an early stage. Subpial cortical lesion pathogenesis is associated with inflammation of the overlying leptomeninges. 3, 8, 9 Progressive cases with significant leptomeningeal inflammation at postmortem had a gradient of neuronal, neuritic, and glial cell loss, 4 which are substrates for cortical thinning and atrophy measured by MRI. 25 High-resolution T2* weighted MRI has highlighted that the greatest changes affect the outer 25% of the cortex at the earliest stage of the disease and that these signal changes are most significant in the sulci, a common site of subpial lesion pathology. 5, 26 More generally, those patients with more cortical lesions and/or greater cortical atrophy have greater cognitive dysfunction and attain disability milestones more rapidly, 27-30 although cognitive and neuropsychiatric dysfunction are important indicators of cortical pathology even in the absence of classical MS clinical features. 31 Our finding of subpial lesions in a cohort of patients who died following a short disease course supports a key role for cortical pathology in the disease outcome. This report adds weight to the recognized need to be able to detect subpial lesions in vivo so that we have a more complete picture of the patient's disease. Numerous, small, intracortical lesions (type 2 lesions) were seen in early but not in progressive MS. Type 2 lesions are the least common cortical GM lesion and account for the smallest area of demyelination in progressive MS. The increased proportion of larger type 1 and type 4 lesions in later disease may account for this change, whereby the smaller type 2 lesions are subsumed as part of larger neighboring lesions.
WM lesions occupied a greater area than cortical GM lesions in acute MS, which could mean that WM lesions are a dominant pathology site of injury in acute MS. It is important to note that the finding of significant WM demyelination may well reflect a selection bias in neuropathological studies. Selection of tissue blocks at initial brain dissection is typically based on the presence of macroscopically visible WM lesions. Evidence for possible ascertainment bias is supported by our observation that WM lesion size was no different in later disease in samples selected based on anatomical region of interest rather than on available visible WM lesions. However, the suggested mechanisms involved in the formation of subpial lesions would mean that they are slower forming and might only accumulate over a longer period than acute WM lesions. Our study was principally focused on cortical and not WM pathology in early MS. Subpial cortical GM lesions cannot be seen macroscopically, meaning that blocks cannot be preselected for this lesion type. In addition, there was no suggestion of an association between the extent of WM demyelination and GM demyelination in acute MS (Spearman r = 0.06, p = 0.91, comparing lesion area per block), meaning that any bias in block ascertainment should not bias our principal research findings.
Neurodegeneration Occurs in the Earliest Years of the Disease
Earlier neuropathology studies have suggested that inflammation is accompanied by axonal and neuronal pathology at all stages of the disease. 32 In agreement with this, we noted extensive neuron loss in acute MS GM lesions and normal GM in comparison to matched non-diseased controls. The extent of neuron loss was comparable to that seen in the progressive MS cortex, 4, 6, 21, 33 and of a similar magnitude as other GM structures. [34] [35] [36] The significant neurodegeneration in acute MS is supported by evidence that the majority of neuron loss in the spinal cord occurs early in disease 37 and that in progressive MS the greatest neuronal loss is seen in those who experienced the shortest disease duration. 2 Neuronal stress and damage and eventual degeneration may be directly and/or indirectly driven by the local inflammation, perhaps as a consequence of serum protein leakage, 38 the diffusion of cytotoxic mediators from the cerebrospinal fluid (CSF)-filled compartments, 4,39 retrograde damage as a result of pathology along affected tracts, 7 and oxidative damage as a consequence of inflammation 40 and/or mitochondrial dysfunction. 41 The density of activated (CD68 + ) tissue microglia/macrophages was elevated in comparison to normal GM and control GM, which may cause or be a consequence of the neuron loss. Parenchymal T-cell infiltrates were noted, but were not quantitatively different between sampled regions (data not shown), whereas the number of parenchymal B cells was negligible. These findings are different from those seen in some cortical GM lesions sampled en passant at biopsy, where significant parenchymal infiltrates were reported. 24 We believe this lack of compelling evidence for CD3 + T-cell or CD20 show here that cortical neurons in acute MS express transcripts of key complement components. Therefore, not only is there significant focal neuronal loss but many surviving neurons express complement and are stressed or damaged, although we cannot conclude that neuronal complement activation is causal to or in consequence of the degenerative change.
LLSs in MS Cases of Short Disease Duration
Meningeal inflammation in MS has been linked to demyelination of the spinal cord, cerebellum, and forebrain, 3, 11, 12 and similar subpial GM lesions can be induced by stereotactic injection of inflammatory cytokines into the leptomeningeal space of the rodent forebrain. 39 The meninges are an important site of antigen drainage, immune surveillance, and inflammation, and ectopic lymphoid structures are commonly found in the connective tissues associated with other diseases of autoimmune or chronic inflammatory origin. 13 Such structures can be induced by T-follicular helper cells, cytokine networks, and a changing stromal network of connective tissue cells, which may eventually support and sustain lymphocyte activation, B-cell selection, clonal expansion, and production of disease-relevant pathogenic antibodies and other soluble mediators. 46 In keeping with our previous studies demonstrating semiorganized immune cell infiltrates that can often resemble ectopic tertiary lymphoid tissues, we noted LLSs in 4 of 12 acute MS cases, an incidence similar to that seen in progressive MS and in other organ-specific autoimmune diseases. 5, 13 The finding of LLSs in early MS suggests that the burden of injury and/or organ-specific immune signals necessary for LLS formation are evident from the earliest times in some MS cases. LLS formation and maintenance accompany elevated tissue damage and antigen release, 46 and LLS + early MS displayed a greater number of active cortical GM lesions, extensive neurodegeneration, and elevated parenchymal microglial/macrophage activation. Therefore, LLSs could be an important sign of pathological disease activity at all stages of MS. In light of the above and because the presence of ectopic lymphoid tissues in synovial biopsies can stratify those in the early course of rheumatoid arthritis for treatment and is prognostic for outcome, 47, 48 there is a justifiable need to identify LLSs and enhanced leptomeningeal inflammation in people with MS. Recent data suggest that a cytokine/chemokine signature of lymphoid neogenesis is elevated in CSF of MS cases with more cortical lesions and greater meningeal inflammation at postmortem, and the same immune mediators accurately identify those patients presenting with an elevated cortical pathology on MRI at disease onset. 14 Such a combined biological and radiological approach, coupled with measurable clinical variables, 28 could therefore be more powerful in identifying those at the early stages of MS who are most at risk of a more severe disease course.
Areas of Partially De-/Remyelinated Cortical GM and Associated Meningeal Inflammation
Together with an association with subpial cortical pathology, we noted that LLSs were sometimes seen near areas of visibly reduced myelin density that may represent partially de-/remyelinated cortical GM. This affected GM was clearly not completely demyelinated GM, but was very different from region-matched "most" normal GM. The myelinated cortical GM in progressive MS displays significant synaptic, dendritic, axonal, neuronal, and oligodendrocyte loss. 4, 8, 25 We noted that the partially de-/ remyelinated GM contained increased numbers of activated microglia/macrophages, microglia containing recently phagocytosed myelin debris, and damaged neurites. The cortical GM is efficiently remyelinated in MS and its models 49 and is capable of repair following repeated episodes of demyelination, 50 but GM remyelination is difficult to measure at postmortem. It would be important to understand how the partially de-/remyelinated cortical GM associates with nearby demyelination and tract-specific pathology and to what degree the affected tissue represents early demyelination, incomplete remyelination, or partially demyelinated GM. Alongside some of the limitations already discussed, we need to be cognizant that the study of demyelination in small tissue blocks is unlikely to represent the extent of pathology throughout the forebrain. Our findings may also be inadvertently biased in that our small blocks are sampled from brain regions that comprise some of the sites where cortical lesions are most frequently seen in later disease. 5, 9, 10 Tissue block sampling in this study was determined by the availability of suitable material. Additionally, we were unable to match controls and acute MS in terms of age at death (see supplementary Table 1 ). Age is an important determinant of total neuron number in the adult brain, 51 and our findings of significant neuron loss in a younger cohort may have been underestimated. To conclude, we show that meningeal inflammation, neurodegeneration, cortical demyelination, and partially de-/remyelinated GM are notable pathological features of acute MS. Our results suggest that all of these pathologies may begin very early in the clinical disease course and can already be substantial after 2 years since diagnosis. By combining biomarkers of intrathecal inflammation and neurodegeneration, together with the most sensitive imaging methods, it may yet be possible to predict those newly diagnosed with MS who are most at risk of early cortical pathology and the associated cognitive and motor disability, and therefore most in need of aggressive immunotherapy, for the best long-term outcome.
